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Objectives We compared 4-year efﬁcacy and safety of sirolimus-eluting stents (SES) and paclitaxel-
eluting stents (PES) in patients with diabetes mellitus (DM).
Background Four-year comparison of SES with PES in diabetic patients has not been evaluated in a
randomized manner.
Methods This prospective, multicenter, randomized study compared SES (n  200) and PES
(n  200) implantation in diabetic patients. We evaluated 4-year major adverse cardiac events
(MACE) including death, myocardial infarction (MI), and target lesion revascularization (TLR).
Results The 2 groups had similar baseline characteristics. At 2 years, TLR (3.5% vs. 11.0%, log-rank,
p  0.01) and MACE (3.5% vs. 12.5%, log-rank, p  0.01) were signiﬁcantly lower in SES versus PES
group with no difference of death or MI. At 4 years there were no differences in death (3.0% vs.
5.0%, p  0.45) or MI (1.5% vs. 1.0%, p  0.99) between SES and PES group. The TLR (7.5% vs.
12.0%, log-rank, p  0.10) and MACE (11.0% vs. 16.0%, log-rank, p  0.10) were statistically not dif-
ferent between SES and PES group. At multivariate Cox regression, post-procedural minimal lumen
diameter (hazard ratio [HR]: 0.44, 95% conﬁdence interval [CI]: 0.24 to 0.81, p  0.01), hypercholes-
terolemia (HR: 2.21, 95% CI: 1.29 to 3.79, p  0.01), and use of intravascular ultrasound (HR: 0.51,
95% CI: 0.26 to 0.99, p  0.049) were independent predictors of 4-year MACE.
Conclusions Superiority of SES over PES during 2 years was attenuated between 2 years and
4 years in diabetic patients. Use of intravascular ultrasound and larger post-procedural minimal lu-
men diameter were independent predictors of the improved long-term clinical outcomes. (J Am
Coll Cardiol Intv 2011;4:310–6) © 2011 by the American College of Cardiology Foundation
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311Diabetic patients are known to have poor long-term out-
comes after bare-metal stent (BMS) implantation compared
with nondiabetic subjects because of unfavorable coronary
anatomy with small and diffusely diseased vessels and
exaggerated neointimal hyperplasia after BMS implantation
(1–4). Recently, a randomized study and registry showed that
drug-eluting stent (DES) implantation significantly reduced
angiographic restenosis and 2-year clinical cardiac events com-
pared with BMS in diabetic patients (5–7); however, presence
of diabetes mellitus (DM) has still been associated with an
increased risk of restenosis and unfavorable clinical outcomes in
the era of BMS or DES (8–12). Recently, the relative efficacies
of sirolimus-eluting stents (SES) and paclitaxel-eluting stents
(PES) in patients with DM have been evaluated in randomized
and registry studies (13–18). Previous studies found SES to
have greater efficacy than PES in diabetic patients for limited
follow-up duration (16,17), and we also previously performed
a randomized, multicenter, prospective study showing that
SES is superior to PES in reducing angiographic restenosis and
9-month and 2-year cardiac events, mainly driven by reduction
in need of repeat revascularization (DES-DIABETES [Drug-
Eluting Stent in patients with DIABETES mellitus] trial)
(18,19). However, the longer-term (2 year) efficacy and safety of
ES over PES remain controversial. Therefore, to compare
onger-term (2 year) efficacy and safety of 2 DES (SES and
ES) in patients with DM, we report the 4-year clinical results of
he patients included in the DES-DIABETES trial.
ethods
Patient selection. The design, exclusion and inclusion cri-
eria, and the data collection of the DES-DIABETES trial
ave been previously described (18). In brief, this random-
zed study included 400 patients 18 years of age with
ngina pectoris and/or a positive stress test and a native
oronary lesion. The study involved 5 cardiac centers in
orea between May 2005 and March 2006. Patients were
onsidered eligible if they had DM, presented with angina
ectoris or had a positive stress test, or met both criteria and
ad clinically significant angiographic stenosis in a native
oronary vessel with a diameter stenosis 50% and visual
eference diameter2.5 mm. Patients were excluded if they
ad contraindication to aspirin, clopidogrel, or cilostazol;
eft main disease (diameter stenosis 50% by visual esti-
ate); graft vessel disease; left ventricular ejection fraction
30%; recent history of hematologic disease or leukocyte
ount 3,000/mm3 and/or platelet count 100,000/mm3;
epatic dysfunction with aspartate aminotransferase or ala-
ine aminotransferase 3 the upper normal reference
imit; history of renal dysfunction or serum creatinine level
2.0 mg/dl; serious noncardiac comorbid disease with a life
xpectancy1 year; planned bifurcation stenting in the side
ranch; primary angioplasty for acute myocardial infarction
MI) within 24 h; or inability to follow the protocol. Inatients with multiple lesions fulfilling the inclusion and
xclusion criteria, the first stented lesion was considered as
arget lesion. The institutional review board at each partic-
pating center approved the protocol. All patients provided
ritten informed consent.
Randomization and procedures. Once the guidewire had
rossed the target lesion, patients were randomly assigned in
1:1 ratio to SES or PES implantation. After DES
andomization, patients were randomly allocated in a 1:1
atio to the triple antiplatelet group (aspirin, clopidogrel,
nd cilostazol [triple group], n 200) or the dual antiplate-
et therapy (aspirin and clopidogrel [standard group],
 200) (antiplatelet arm) on the basis of a 2  2 factorial
esign with a computer-generated randomization sequence.
andom assignments were stratified according to participa-
ion sites and blocked, with block size of 4 or 6, and were
istributed in sealed envelopes
o each participating center. The
lock size was concealed. From
t least 24 h before the proce-
ure and thereafter, all patients
eceived aspirin (200 mg daily)
nd clopidogrel (loading dose of
00 mg, followed by 75 mg daily
or at least 6 months). Patients
n the triple group received a
oading dose of 200 mg cilosta-
ol immediately after the proce-
ure and 100 mg twice/day for 6
onths.
Coronary stenting was per-
ormed with the standard tech-
ique. The decision of pre-
ilation or direct stenting was
ade by the operator. The use of
ntravenous glycoprotein IIb/
IIa inhibitors was at the discre-
ion of the operators. A 12-lead
lectrocardiogram was obtained after the procedure and
efore discharge. Serum levels of creatine kinase, its myo-
ardial band isoenzyme was assessed 8, 12, and 24 h after
he procedure and thereafter if considered necessary.
Study end point and deﬁnitions. We evaluated 4-year clin-
ical outcomes, including stent thrombosis, target vessel
revascularization (TVR), and major adverse cardiac events
(MACE) including death, MI, and target lesion revascular-
ization (TLR). Q-wave MI was defined by the post-
procedural presence of new Q waves of 0.04 s in 2
contiguous leads. Non–Q-wave MI was defined as a crea-
tine kinase-myocardial band fraction 3 the upper limit
of normal. Target lesion revascularization was defined as a
repeat intervention (surgical or percutaneous) within the
stent or in the 5-mm proximal or distal segments adjacent to
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
DM  diabetes mellitus
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
MLD  minimal lumen
diameter
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationthe stent. Target vessel revascularization was defined as a
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312reintervention of a lesion in the same epicardial vessel.
Target lesion revascularization or TVR was considered
clinically driven if prompted by symptoms consistent with
myocardial ischemia, preceded by an abnormal stress test
result consistent with myocardial ischemia, if there were
other electrocardiographic changes consistent with myocar-
dial ischemia, or if the lesion diameter stenosis was more
than 70% at follow-up (20). Stent thrombosis was defined as
any of the following after the procedure: angiographic
documentation of stent occlusion with or without the
presence of thrombus associated with an acute ischemic
event, unexplained sudden death, or MI not clearly attrib-
utable to another coronary lesion (21,22).
Coronary angiograms were obtained after intracoronary
nitroglycerin administration. Procedure (baseline), post-
procedure, and follow-up angiograms were submitted to the
angiographic core analysis center (Asan Medical Center,
Seoul, Korea). Digital angiograms were analyzed with an
automated edge detection system (CASS II, Pie Medical,
Maastricht, the Netherlands). The core laboratory was
blinded to the treatment assignment.
Follow-up. Repeat coronary angiography was mandatory at
6 months after stenting or earlier if indicated by clinical
symptoms or evidence of myocardial ischemia. Clinical
follow-up visits were scheduled at 30, 90, 180, and 270 days
after procedure and every 3 months thereafter. At every
visit, physical examination, electrocardiogram, cardiac
events, angina recurrence, and medication were monitored.
Table 1. Baseline Clinical and Characteristics
Variable
SES
(n  200)
PES
(n  200) p Value
Age, yrs 61.1 8.9 60.7 8.8 0.62
Men 122 (61.0%) 110 (55.0%) 0.22
Hypertension 114 (57.0%) 124 (62.0%) 0.31
Treatment of diabetes mellitus 0.97
Dietary therapy alone 18 (9.0%) 19 (9.5%)
Oral hypoglycemic agent 150 (75.0%) 148 (74.0%)
Insulin 32 (16.0%) 33 (16.5%)
Glycosylated hemoglobin 7.7 1.8% 7.8 1.6% 0.68
Total cholesterol 200 mg/dl 55 (27.5%) 63 (31.5%) 0.38
Current smoker 54 (27.0%) 57 (28.5%) 0.74
Previous PCI 25 (12.5%) 25 (12.5%) 0.99
Previous CABG 4 (2.0%) 3 (1.5%) 0.99
Clinical diagnosis 0.10
Stable angina 86 (43.0%) 82 (41.0%)
Unstable angina 80 (40.0%) 67 (33.5%)
Acute myocardial infarction 34 (17.0%) 51 (25.5%)
Left ventricular ejection fraction, % 59 10 58 10 0.37
Multivessel disease 119 (59.5%) 137 (68.5%) 0.17
Values are expressed as mean SD or n (%).
CABG coronary artery bypass surgery; PCI percutaneous coronary intervention;
SES sirolimus-eluting stent(s).At each participating center, patient data were recordedprospectively on standard case report forms and gathered in
the central data management center (Asan Medical Center).
All adverse clinical events were adjudicated by an indepen-
dent events committee blinded to the treatment groups.
Statistical analysis. Analyses of 2 groups were performed
according to the intention-to-treat principle. Continuous
variables are presented as mean  SD and compared with
Student unpaired t or Mann–Whitney U tests. Categorical
variables are presented as numbers or percentages and were
compared with chi-square or Fisher exact tests. The rate of
cardiac events during 4-year follow-up period was analyzed
with the Kaplan-Meier analyses, and the difference between
rates was assessed by the log-rank, test. Cox proportional
hazards models were used to examine the association of
stent type with the risks of clinical events. The proportional-
hazards assumptions of the models were violated, because
TLR and MACE rate were exactly opposite before and after
the 2-year time point. Thus, to evaluate the events of the
first 2 years (2 years after implantation) and of the second
2 years (2 years after implantation), time-dependent Cox
model were performed with interaction of stent type and I
(time 2 years), where I(·) is indicator function. Further-
more, to evaluate very late-occurring events (2 years after
implantation), a landmark analysis was performed with a
pre-specified landmark time point at 24 months. Patients
who survived without MI or revascularization during the
initial 24 months were included in this analysis. Univariate
and multivariable Cox proportional hazards models were
used to examine the predictor of cardiac event. All variables
in Tables 1 and 2 were tested, and variables with a p value
Table 2. Angiographic Characteristics and Procedural Results
Variable
SES
(n  200)
PES
(n  200) p Value
Reference diameter, mm 2.80 0.43 2.80 0.43 0.96
Lesion length, mm 25.8 12.9 27.2 14.2 0.34
Stented length, mm 32.52 13.9 33.2 15.2 0.67
Target vessel 0.71
Left anterior descending artery 122 (61.0%) 118 (59.0)
Left circumﬂex artery 28 (14.0%) 25 (12.5%)
Right coronary artery 50 (25.0%) 57 (28.5%)
Procedure-related non–Q MI 16 (8.0%) 18 (9.0%) 0.72
Maximal inﬂation pressure, atm 15.4 3.6 14.6 3.6 0.03
Use of intravascular ultrasound 67 (33.5%) 64 (32.0%) 0.75
Use of glycoprotein IIb/IIIa inhibitor 11 (5.5%) 7 (3.5%) 0.47
Pre-dilation before stenting 194 (97.0%) 190 (95.0%) 0.45
Post-stenting adjunctive balloon dilation 97 (48.5%) 87 (43.5%) 0.32
Largest balloon size for adjunctive
dilation, mm
3.18 0.43 3.25 0.42 0.10
Multivessel stenting 64 (32.0%) 69 (34.5%) 0.60
Number of used stents at the target lesion 1.28 0.49 1.28 0.56 0.94
Values are expressed as mean SD or n (%).MImyocardial infarction; other abbreviations as in Table 1.
b
w
b
s
T
c
d
1
l
i
l
p
o
4
a
g
p
a
l
p
a
l
p
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 3 , 2 0 1 1 Lee et al.
MA R C H 2 0 1 1 : 3 1 0 – 6 4-Year Outcomes of DES for Diabetic Patients
3130.10 in univariate analyses were candidates for the multi-
variable Cox proportional hazards models. A backward
elimination process was used to develop the final multivari-
able model, and adjusted hazard ratios (HRs) with 95%
confidence intervals (CIs) were calculated. Schoenfeld re-
siduals test was used to verify that the proportional-hazards
assumptions were not violated (23).
All p values were 2-sided, and p  0.05 was considered
significant. Statistical analysis was performed with SAS soft-
ware (version 9.1, SAS Institute, Cary, North Carolina).
Results
Baseline characteristics of the patients. Table 1 shows the
aseline clinical characteristics of the study groups. There
ere no significant differences between the 2 groups in
aseline clinical characteristics or risk factors. Table 2
hows angiographic characteristics and procedural results.
he 2 groups had similar anatomical and procedural
haracteristics.
Clinical outcomes. At 2 years, there was no difference in
eath or MI (Table 3). However, the rates of TLR (3.5% vs.
1.0%, log-rank, p  0.01) and TVR (5.5% vs. 12.0%,
og-rank, p 0.01) were significantly lower in the SES than
n the PES group. Clinically driven TLR (3.0% vs. 9.0%,
og-rank, p  0.01) and TVR (4.0% vs. 10.5%, log-rank,
 0.01) rates were also significantly lower in the SES than
in the PES group. The MACE rate was significantly lower
in the SES than in the PES group (3.5% vs. 12.5%, log
rank, p  0.01), as was the composite of death, MI, or
TVR (5.5% vs. 14.0%, p  0.01). A 4-year clinical
follow-up was performed in 97% of the study population
(Table 3). Sixteen deaths (6 in SES patients and 10 in
PES patients, p  0.45) occurred. Myocardial infarction
ccurred in 3 SES and 2 PES patients (p  0.99). During
years, 8 stent thromboses occurred in the SES group (1
cute, 7 very late) and 3 (3 very late) occurred in the PES
roup (p  0.22). Of 10 very late stent thrombosis
atients, 5 suffered from stent thrombosis during dual
ntiplatelet therapy. The rates of TLR (7.5% vs. 12.0%,
og-rank, p  0.10) and TVR (9.5% vs. 14.0%, log-rank,
 0.14) were statistically not different between the SES
nd PES groups. Clinically driven TLR (7.0% vs. 9.5%,
og-rank, p  0.29) and TVR (8.0% vs. 12.0%, log-rank,
 0.15) were also similar between the 2 groups.
Incidence of MACE was also statistically not different
between the SES and PES groups (11.0% vs. 16.0%,
log-rank, p  0.10), as was the composite of death, MI,
or TVR (13.0% vs. 18.0%, log-rank, p  0.15).
The Kaplan-Meier curves for TLR and MACE are
depicted in Figure 1. The benefits of SES for reduction in
TLR and MACE at 2 years were attenuated during long-
term follow-up to 4 years. In landmark analysis from 2
years, the TLR and MACE rates tended to be higher in the pSES group versus the PES group, but the difference did not
reach statistical significance.
Predictor of clinical outcomes. Variables with a p value
0.10 in univariate analyses were candidates for the multi-
variable Cox proportional hazards models. In the final
multivariable model, hypercholesterolemia, clinical diagno-
sis, post-procedural minimal lumen diameter (MLD), and
use of intravascular ultrasound were tested. An independent
predictor of 4-year TLR was post-procedural MLD (HR:
0.28, 95% CI: 0.14 to 0.57, p  0.01). Post-procedural
MLD (HR: 0.44, 95% CI: 0.24 to 0.81, p  0.01),
hypercholesterolemia (HR: 2.21, 95% CI: 1.29 to 3.79,
p  0.01), and use of intravascular ultrasound (HR: 0.51,
95% CI: 0.26 to 0.99, p  0.049) were independent
Table 3. Clinical Outcomes at 4 Years
Variable
SES
(n  200)
PES
(n  200) p Value
2-yr outcomes
Death 0 3 (1.5%) 0.25
Cardiac 0 2 (1.0%)
Noncardiac 0 1 (0.5%)
MI 1 (0.5%) 2 (1.0%) 0.99
Q-wave 0 2 (1.0%)
Non–Q-wave 1 (0.5%) 0
TLR 7 (3.5%) 22 (11.0%) 0.01
Stent thrombosis 2 (1.0%) 0 0.50
Acute (1 day) 1 (0.5%) 0
Subacute (1 day–1 month) 0 0
Late (1 month–12 months) 0 0
Very late (12 months) 1 (0.5%) 0
TVR 11 (5.5%) 24 (12.0%) 0.01
Death/MI/TVR 11 (5.5%) 28 (14.0%) 0.01
MACE (death/MI/TLR) 7 (3.5%) 25 (12.5%) 0.01
4-yr outcomes
Death 6 (3.0%) 10 (5.0%) 0.45
Cardiac 5 (2.5%) 5 (2.5%)
Noncardiac 1 (0.5%) 5 (2.5%)
MI 3 (1.5%) 2 (1.0%) 0.99
Q-wave 0 2 (1.0%)
Non–Q-wave 3 (1.5%) 0
TLR 15 (7.5%) 24 (12.0%) 0.18
Stent thrombosis 8 (4.0%) 3 (1.5%) 0.22
Acute (1 day) 1 (0.5%) 0
Subacute (1 day–1 month) 0 0
Late (1 month–12 months) 0 0
Very late (12 months) 7 (3.5%) 3 (1.5%)
TVR 19 (9.5%) 28 (14.0%) 0.21
Death/MI/TVR 26 (13.0%) 36 (18.0%) 0.21
MACE (death/MI/TLR) 22 (11.0%) 32 (16.0%) 0.19
Cumulative incidence represents simple proportion of the events in the population.
MACE  major adverse cardiac event(s); TLR  target lesion revascularization; TVR  target
vessel revascularization; other abbreviations as in Tables 1 and 2.redictors of 4-year MACE.
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314Discussion
The major findings of this study are that: 1) the superiority
of SES over PES in TLR and MACE at 2 years was
attenuated during long-term follow-up to 4 years, with no
differences in death or MI in diabetic patients; 2) use of
intravascular ultrasound and larger post-procedural MLD
were independent predictors of improved long-term clinical
outcomes; and 3) 10 (2.5%) cases of very late stent throm-
bosis occurred, suggesting that more optimal stent implan-
tation, DES with biocompatible polymer, bioabsorbable
DES, or more effective antiplatelet therapy might be needed
to improve long-term clinical outcomes.
Restenosis and subsequent TLR in diabetic patients are
still important and persist, albeit to a lesser extent, with
DES. Until recently, there have been heterogeneous results
of clinical outcomes with SES versus PES in diabetic
persons (13–18). Recently, we reported the results of the
DES-DIABETES study (18), confirming the findings of
the ISAR-DIABETES (Intracoronary Stenting and Angio-
graphic Results: Do Diabetic Patients Derive Similar Ben-
Figure 1. Kaplan-Meier Curves for Outcome According to Stent Type Durin
(A) Cumulative incidence of 4-year target lesion revascularization (TLR). (B) Lan
before and after 2 years; p  0.0054. (C) Cumulative incidence of major adver
analysis of MACE (death, myocardial infarction, and TLR). The HRs of stent type
interval.efit from Paclitaxel-Eluting and Sirolimus-Eluting Stents)study (16), which showed that SES significantly reduced
restenosis with statistically insignificant reduction of repeat
revascularization compared with PES in diabetic patients.
The DES-DIABETES trial added the statistical signifi-
cance in reduction of repeat revascularization as well as
angiographic restenosis. We also reported that superiority of
SES over PES in risks of TLR and MACE was maintained
up to 2 years in the DES-DIABETES trial (19).
In the present study, we found that the superior clinical
results of SES over PES at 2 years in terms of reduction in
TLR and MACE were no longer apparent at 4 years,
because late TLR increased more for SES than PES
between 2 and 4 years. In the SIRTAX (Sirolimus-Eluting
Versus Paclitaxel-Eluting Stents for Coronary Revascular-
ization) LATE trial (24), clinical superiority of SES over
PES at 1 year in TLR and MACE was lost during 5-year
follow-up, mainly driven by insignificantly higher repeat
revascularization in the SES group between 1 year and 5
years. These findings were explained by 5-year angiographic
follow-up study of the SIRTAX LATE trial, in which
ar Follow-Up
k analysis of TLR. Hazard ratios (HRs) of stent type were time-dependent
diac events (MACE) (death, myocardial infarction, and TLR). (D) Landmark
time-dependent before and after 2 years; p  0.0013. CI  conﬁdenceg 4-Ye
dmar
se car
weresuperiority of 8-month in-stent late loss in SES versus PES
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315(0.12  0.36 mm vs. 0.25  0.49 mm, p  0.001) was no
longer apparent at 5-year follow-up angiography between
SES and PES groups (0.30 0.51 mm vs. 0.37 0.51 mm,
p 0.21). Higher late loss between 8 months and 5 years in
the SES versus PES groups of the SIRTAX LATE trial
might explain our results of higher late TLR of the SES
versus PES group between 2 and 4 years. These findings
suggest that the restenosis process after DES implantation
is delayed and late loss continuously increases.
By multivariate analysis, post-procedural MLD was iden-
tified as a predictor of 4-year TLR and MACE. Post-
procedural MLD has been known as the predictor of
angiographic restenosis (25) in diabetes and in real practice
with different complex lesions (26). Because late restenosis
(beyond 6 months) after DES implantation resulted mostly
from neointimal hyperplasia (4,25,27), binary restenosis and
need for revascularization might be more likely to occur in
patients with smaller post-procedural MLD. Therefore,
achievement of larger post-procedural MLD improved the
4-year clinical outcomes in diabetic patients.
In our study, there was no difference in the incidence of
death (3.0% vs. 5.0%, p  0.45) or MI (1.5% vs. 1.0%,
p  0.99) between the SES and PES groups. These
findings are consistent with a network meta-analysis of 38
trials showing no differences in the risks of death or MI for
SES, PES, and BMS patients for up to 4 years (28) and the
SIRTAX LATE trial (24). However, stent thrombosis
continuously occurred during the follow-up period. In our
study, very late stent thrombosis occurred in 10 patients
(2.5%). Of these, 5 patients suffered from stent thrombosis
during dual antiplatelet therapy. Furthermore, 29% (10 of
34) of MACE between 1 year and 4 years of overall
population was associated with very late stent thrombosis,
which is consistent with the previous study (29). Recently, 1
study found that very late stent thrombosis after DES
implantation was related to stent malapposition (73.9%),
probably due to inflammatory response to the polymer and
disease progression with neointimal rupture (43.5%) (30).
These results underlie the importance of aggressive medical
treatment, optimal stent implantation, development of DES
with biocompatible or bioabsorbable polymers, or bioab-
sorbable DES (31–33).
Study limitations. First, stress tests to detect myocardial
schemia were not routinely performed during the 4-year
ollow-up. Considering that silent myocardial ischemia
ccurs in 1 in 5 asymptomatic patients with type 2
iabetes in the DIAD (Detection of Ischemia in Asymp-
omatic Diabetics) study (34), there might be a possible bias
ssociated with clinical decisions related to TLR. Second,
ur study was initially designed to find the difference of
ngiographic restenosis between SES and PES at 6-month
ollow-up angiography. Therefore this study is underpow-
red to evaluate the differences in TLR, MACE, stent
hrombosis, death, or MI. However, this study is a random-zed and dedicated study for diabetic patients, and the
esults clearly showed that superiority of SES over PES up
o 2 years in TLR and MACE was attenuated at 4-year
ollow-up. These findings give us the message that the 2
rst-generation DES have a similar efficacy during long-
erm follow-up in diabetic patients. Third, our multivariable
odel might be overfitted on the basis of the small numbers
f end point events.
onclusions
The superiority of SES over PES in TLR and MACE at 2
years was attenuated during long-term follow-up to 4 years
with no differences in death or MI in diabetic patients.
Post-procedural MLD served as an independent predictor
of 4-year TLR and MACE. A substantial number (29%) of
MACE after first-generation DES was related to very late
stent thrombosis during long-term follow-up.
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